Oramed’s Chinese Partner, HTIT, Successfully Completes Phase 3 Oral Insulin Clinical Trial/Submits Marketing Authorization Application in China

Oramed Pharmaceuticals. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) strategic partner, Hefei Tianhui Biotechnology (HTIT), has completed its Phase III trials of oral insulin for type 2 diabetes in China and is…

Continue Reading Oramed’s Chinese Partner, HTIT, Successfully Completes Phase 3 Oral Insulin Clinical Trial/Submits Marketing Authorization Application in China